Our studies of the relationship between prolactin structure and function have resulted in the development of pure prolactin-receptor antagonists. These molecules prevent endogenous prolactin from ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

The addition of β-adrenergic receptor antagonists to a medical regimen for heart failure that includes angiotensin-converting enzyme (ACE) inhibitors as background therapy has been associated ...

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular ...